Biomarkers & Treatment Guidance
|
|
- Jeffrey Garry Hampton
- 5 years ago
- Views:
Transcription
1 Biomarkers & Treatment Guidance Alan S. Maisel MD FACC Professor of Medicine, University of California, San Diego, Director, CCU and Heart Failure Program San Diego VA Medical Center
2
3
4 Easy to measure Inexpensive Can be point-of- care Results back in less than one hour Reliable surrogates
5 Biomarkers Clinical Relevance in Heart Disease Over the last decade, measurement of biomarkers is being considered as an add-on to routine laboratory investigations in the management of HF 1,2 Levels of the different biomarkers may indicate a spectrum of underlying pathophysiological aspects of HF 1 Currently, biomarkers are considered to be potential supplementary aids for the diagnosis, prognostication, and management of patients Neurohormones Norepinephrine Renin, Angiotensin II Copeptin, Endothelin Vascular system Homocysteine Adhesion molecules (ICAM, P-selectin) Endothelin Adiponectin C-type natriuretic peptide Inflammation C-reactive protein sst2, TNF, APO-1, GDF-15 Pentraxin 3, Adipokines Cytokines, Procalcitonin Osteoprotegerin Biomarkers in HF Myocardial stress Natriuretic peptides Mid-regional Pro-adrenomedullin Neuregulin, sst2 Cardio-renal syndrome Creatinine Cystatin C, NGAL Β-Trace protein Myocardial Injury Cardiac troponins High sensitivity cardiac troponins Myosin light-chain kinase 1 Heart-type fatty acid binding protein Pentraxin 3 Oxidative stress Oxidized LDL Myeloperoxidase Urinary biopyrins Urinary and plasma isoprostanes Plasma malondialadehyde Matrix and cellular remodeling Galectin-3 sst2, GDF-15 MMPs, TIMPs Collagen propeptides Osteopontin Adapted from Ahmad, T. et al. Nat. Rev. Cardiol doi: /nrcardio CHF, chronic heart failure; GDF-15, growth differentiation factor 15; HF, heart failure; NGAL, neutrophil gelatinase-associated lipocalin; sst2, soluble suppression of tumorigenicity 2; TNF, tissue necrosing factor; APO-1 apolipoprotein 1; GDF growth differentiating factor 1. Yancy CW. et al. J Am Coll Cardiol. 2013;62(16):e147-e Maisel AS. et al. Nat Rev Cardiol. 2012;9(8):
6 Objectives of Biomarker Testing in Heart Disease Diagnosis 1 Condition X To establish or refute a diagnosis To understand the underlying pathophysiologic processes Biomarker Risk Stratification/Screening 1 To determine the presence or severity of disease To detect adverse consequences Monitoring/Therapeutic Guidance 1 Outcome A To facilitate selection of an appropriate therapeutic intervention Many To guide biomarkers or monitor responses may be to risk factors themselves; treatment therefore, may be potential targets of therapy 2 HF, heart failure. Intervention Outcome B 1. Morrow DA, et al. Circulation. 2007;115: Kalogeropoulos AP, et al. Prog Cardiovasc Dis. 2012;55(1):
7 The Epidemic of Heart Failure Prevalence Incidence Mortality Hospital Discharges Outpatient Visits Cost 5,100, ,000 50% at five years 1,023, million $39.8 billion Heart failure is common, costly, and deadly Prevention, diagnosis, risk stratification, monitoring, and managing heart failure is challenging There has been great interest in the clinical role of biomarkers in heart failure American Heart Association Heart and Stroke Statistical Update. Dallas, Tex: American Heart Association; 2013.
8 Sensitivity Accuracy is 90% Optimal cut-off point 100 pg/ml BNP=50 pg/ml BNP=80 pg/ml BNP=100 pg/ml BNP=125 pg/ml BNP=150 pg/ml Positive predictive value=75% BNP 100 pg/ml Test positive BNP <100 pg/ml Test negative Final Diagnosis Heart Failure Final Diagnosis NOT Heart Failure Sensitivity =90% 615 Specificity =73% Negative predictive value=90 % Specificity Maisel AS et al. N Engl J Med. 2002;347:
9 Indecision Clarification of Diagnosis & BNP 45% 40% 35% 30% 25% 20% 15% 10% 5% 0% 43% Clinical Evaluation BNP reduces clinical indecision by 74% * P < % Clinical Evaluation and BNP
10 PAW (mm Hg) Changes in BNP Mirror changes in PAW* During Treatment of Acute Heart Failure N = 15 (responders) PAW BNP BNP (pg/ml) baseline *Pulmonary artery wedge. Hours Kazenegra, Maisel, A. et al. J Cardiac Failure, Vol. 7, No. 1, 2001
11 In volume overloaded patients: NP level = baseline NP (dry) + change due to increased volume (wet) BNP level (pg/ml) 2500 Wet (change due to volume overload) 2000 Dry ( NYHA Euvolemic state) I II III IV NYHA Class - Euvolemic (Dry) BNP
12
13 NP Guided Therapy GUIDE-IT Trial Hospitalization for HF LVEF 40 within 12 months NT-proBNP >2000 pg/ml or BNP >400 pg/ml during index hospitalization Screening Randomized within 2 weeks of hospital discharge Usual Care N = 550 Biomarker Guided NTproBNP <1000 pg/ml N = 550 Randomization Follow-up: 2 weeks, 6 weeks, 3 months, then Q3 month for months Additional 2 week follow-up after changes in therapy Follow-up The GUIDE-IT study is designed to provide the definitive answer about the safety, efficacy, and cost-effectiveness of NP-guided therapy for chronic systolic HF HF, heart failure; LVEF, left ventricular ejection fraction; NP, natriuretic peptide; NT-proBNP, N-terminal pro B-type natriuretic peptide; Q3, every 3 months. Felker GM. et al. JACC Heart Fail. 2014;2(5):
14 Ledwidge et al. JAMA 2013 STOP-HF trial St Vincent s Screening to Prevent Heart Failure Study Routine care (n=677) Routine PCP care Cardiology care PRN Vs. BNP-directed care (n=697) Annual BNP check If BNP >50 pg/ml at any time: cardiology consult, echo, nurse-coaching 1 Endpoint: LV systolic or diastolic dysfunction, or heart failure 2 Endpoints: Emergency hospitalization for arrhythmia, TIA, stroke, MI, PE/DVT, HF
15 Ledwidge et al. JAMA 2013 STOP-HF trial: results Reduction in primary endpoint (p=0.003)
16 Ledwidge et al. JAMA 2013 STOP-HF Also reduced emergency hospitalizations for MACE BNP group received renin-angiotensinaldosterone system-based therapy
17 NP in management of Heart Failure Accepted Indications New Diagnosis of HF in Community Differentiating dyspnoea in ER Prognosis at hospital d/c ADD Emerging Indications Guide to therapy Predicting outpatient deterioration Driver of prevention strategies
18 NT-proBNP pg/ml BNP pg/ml PARADIGM-HF: NT-proBNP and BNP NT-proBNP BNP Months LCZ696 Enalapril
19 Confounders of NP interpretation * Delineates likely elevation from Ventricular stretch Higher NP levels than expected Lower NP levels than expected Increasing age* ACS* Renal insufficiency RV dysfunction* Atrial fibrillation Obesity Flash pulmonary edema Pericarditis/Tamponade Genetic polymorphisms Burned-out Cardiomyopathy Pulmonary hypertension* Pulmonary embolism* Anemia/high output states* Sepsis Mitral Regurgiation*
20 Heart Failure + Infection Heart failure plus any infection may occur in up to 20% of hospitalized heart failure patients. Hospital Mortality may be up to 20% (versus 5%) in heart failure patients with untreated infections
21 Müller B. et al., Crit.Care Med The likelihood and severity of bacterial infection increase with increasing PCT levels
22 PCT in "Antibiotic Stewardship": -> Reducing Duration of Antibiotic Therapy in patients with CAP Prospective interventional trial: 302 patients Tailoring of antibiotics treatment to the individual patient needs Reduction of average treatment duration from 12 to 5 days. Same outcome! (Safety) Christ-Crain M et al. Am J Respir Crit Care Med Apr 7
23
24
25 A combination of Natriuretic Peptide and PCT can be used to better diagnose dyspneic patients Maisel Eur J HF 2012
26 Improved Management of heart failure with ProcAlCiTonin
27 8-24 h Max. 8 h IMPACT-EU Presentation in the ED Routine clinical assessment chief complaint SOB Informed Consent, Evaluation of In/Exclusion Criteria Randomization PCT guided group N= 900 PCT blind group N= 900 blood sampling, PCT measurement blood sampling PCT > 0.2 PCT =< + Abx 0.2 -ABx Standard diagnostics + ABx - ABx Follow-up PCT day 1 Follow-up PCT day 1 Follow up blood sample day 1
28 Positive Troponin in Acute Heart Failure: What Does it Mean? What Should I Do?
29 Choose: 1 or 2? When faced with an AHF patient with a positive troponin, the ER will.
30 Choose: 1 or 2? When faced with an AHF patient with a positive troponin, the ER will. 1. Carefully consider the clinical context, review all past records, discuss with the cardiologist or primary care physician of record and in consideration of the patients other co-morbid conditions, determine whether admission or discharge with early follow up is best.
31 Choose: 1 or 2? When faced with an AHF patient with a positive troponin, the ER will. 1. Carefully consider the clinical context, review all past records, discuss with the cardiologist or primary care physician of record and in consideration of the patients other co-morbid conditions, determine whether admission or discharge with early follow up is best. 2. Admit the patient
32 Cardiac Troponins Overview and Mechanism of Troponin Release Increased Wall Stress Epicardial CAD Oxidative Stress Reversible Injury Cardiac Troponin Release Myocyte Apoptosis Myocyte Necrosis Troponin Degradation Products Neurohormo nal Activation Altered Calcium Handling Inflammato ry Cytokines 32
33 In-Hospital Mortality According to Conventional ctni or ctnt Quartile Patients with Acute Decompensated Heart Failure Data from the ADHERE Registry Ischemic heart disease was not a useful discriminator of troponin status or mortality with a positive troponin result Peacock WF IV et al. N Engl J Med 2008;358:
34 Event Free (Death or Readmission) Cardiac Troponins Role in Prognosis 90-day Mortality and HF-related Readmissions by Discharge Troponin I Levels Troponin <23.25 ng/l (59 subjects) Troponin >23.25 ng/l (85 subjects) Time (Days) Patients with a discharge TnI >23.25 ng/l had significantly higher 90-day mortality and HF-related readmissions than patients with a discharge TnI <23.25 ng/l (P=0.003, HR, 3.547) 2 ACS, acute coronary syndrome; AHF, acute heart failure; CHF, chronic heart failure; HR, hazard ratio; hs-ctnt, high-sensitive cardiac troponin T; TnI, troponin I. 1. Maisel. et al. Circulation. 2007;116(5):e
35 Cardiac Function AHF Contributes to the Progression of HF Goal: prevent myocardial and renal damage and implement life-saving therapies Hospitalization Hypothesis: with each hospitalization there is myocardial and/or renal damage Hospitalization Hospitalization Time Gheorghiade et al. Am J Cardiol 2005;96(6A):11G 17G
36 Prognostic Value of a >20% hs-ctnt Increase From Baseline and Effects of Serelaxin Percent of patients with hs-ctnt increase Troponin T p = Metra et al. JACC Placebo Serelaxin
37 PARADIGM-HF: median hs-tnt (µg/l) concentration by visit Randomization Prior to Run-in Randomization 4 weeks 8 months
38 Recommendations for using troponin in Acute Heart Failure Exclude type I MI (ACS) Rising/falling pattern Signs/symptoms of ischemia Imaging evidence May rise and fall even without MI ADHF rise; treatment of HF fall Tn >99 th percentile worse outcome Regardless of type I MI/ACS
39 Proportion of Adults with Detectable ctnt (>3ng/L) Dallas Heart Study Cardiovascular Health Study ARIC
40 Proportion of subjects with elevated contemporary ctnt levels in the general population Total population ctnt 0.01 ng/ml = 0.7% Risk factor determinants: (DM, HF factor, LVH, or CKD) Wallace TW. Circulation 2006;113:
41 Left Ventricular Hypertrophy Heterogeneous Progression to Heart Failure
42 The malignant phenotype of LVH ctnt+ defined as > 3 ng/l Neeland I. J Am Coll Cardiol 2013;61:187 95
43 Risk of New Onset Heart Failure Ambulatory Older Adults Stratified by ctnt level defilippi JAMA 2010;304:
44 ng/ml Cardiac Troponin T levels Pre and post marathon in 25 adults > 50 years Karlstedt et al. Journal of Cardiovascular Magnetic Resonance 2012, 14:58
45 Association of Physical Activity, NT-proBNP and hs ctnt level in older adults The ActiFE Study Duration of walking measured by accelerometer over 1 week Klenk J. J Epidemiol Community Health 2013;67:
46 Association of moderate physical activity, rise in hs ctnt level and risk of new onset heart failure Composite score is a sum of walking pace and duration of moderate to intense leisure activities A higher score is a faster pace and longer duration of activity. Significant increase in hs ctnt defined as > 50% rise from the baseline level. defilippi C. J Am Coll Cardiol 2012;60:2539-4
47 sst2- has evolved to be a useful marker
48 Soluble ST 2 ST-2: Suppressor of tumorigenicity 2 (IL-1 receptor-like-1) Member of Interleukin-1 receptor family ST2 gene encodes isoforms by alternative promotor splicing membrane bound receptor: ST-2L (Profibrotic signaling) soluble truncated form: sst-2 (Decoy receptor) IL-33: Interleukin 33, Binds to ST-2L & Inhibits Profibrotic signaling ST2L Interleukin-33 (IL-33) X Pro-fibrotic Signaling
49 sst-2 binds IL-33 & inhibition of ST-2L profibrotic signaling Fibrosis sst2l ecoy Receptor ST2L Interleukin-33 (IL-33) X Pro-fibrotic Signaling
50 Single ST2 Cut-point: > ng/ml = RISK
51 Measured levels of ST2 and BNP on consecutive admissions for AHF Looked at admissions in previous 3 months Looked at admissions in the 3 months following discharge Related ST2 and BNP levels to total number of admissions ROC curve analysis to predict probability of other admissions when they come to hospital ( ie readmission risk)
52 Admissions Admissions ST2 and Admissions Over 6 Months BNP and Admissions Over 6 Months 10 8 R² = ST2 (ng/ml) Wetterson, Maisel AJM R² = BNP (pg/ml) 52
53 Maisel s Frequent-Flyer Index
54 Changes one might consider on the basis of a biomarker prior to discharge Extra hospital time One week follow up Home nursing Telemonitoring More aggressive titration of medications
55 ST2 in Ambulatory Heart Failure
56 A Large Number of Eligible Patients are Untreated U.S. Data ACEI/ARB BB MRA Hydral/Nitr ate CRT ICD Number of Eligible Patients 2,459,644 2,512, , , ,151 1,725,732 Fonarow et al. Am Heart J 2011
57 Serial ST2 Measurements Categorize Responder Status ST2 Responders ST2 Non-Responders Decrease 50% Decrease 25 49% Adjusted for ADHERE Risk Factors and BNP change. Increase or decrease <25% Basel ADHF cohort 57
58 ST2 Predicts Response to Treatment: Aldosterone Blockade in STEMI Eplerenone prevents adverse ventricular remodeling ST2 predicts which pts are most at risk AND which pts will benefit most from aldosterone blockade Weir AP, et al. J. Am. Coll. Cardiol. 2010;55; High and low ST2 separated at median. Eplerenone attenuates remodeling more in pts with higher baseline ST2.
59 Old biomarkers become new guided treatment biomarkers Sodium Potassium Pulmonary pressure Heart rate Tolvaptan New K drugs CardioMems Ivabridine
60 The Future is closer than we think Screening for risk of disease: Purpose is to Prevent the Disease 1. LV dysfunction 2. Fibrosis 3. CAD NP, hstroponin, ST2 Condition X Biomarker Intervention And a new one: Proneurotensin Outcome A Outcome B. 60
61 What if? There was a protein biomarker associated with insulin and fasting blood glucose Higher in women predicts incident diabetes mellitus in females independent from glucose and insulin And also predicts incident CVD Death Breast cancer Slide 61
62 Fat abnormalitydiet,lipids, etc DIABETES CARDIOVASCULAR DISEASE BREAST CANCER 62
63 Proneurotensin (pro-nt) Neurotensin is not stable in-vivo and in-vitro Not applicable for laboratory routine use Proneurotensin (1-117) = pro-nt Stable fragment of the precursor molecule pro-nt: stable surrogate marker for Neurotensin Slide 63
64 Proneurotensin (pro-nt) released Neuronal Functions Neurotransmitter Influences dopaminergic transmission Signals satiety Pancreatic Functions Insulin resistance Elevated pro-nt levels Gastrointestinal Functions The insulin of fat Inhibition of gastric and small bowel motility Neurotensin and the Neurotensin 1 receptor are expressed in breast cancer tissue Missing link between diet and breast cancer? Increased risk of stroke, coronary heart disease and diabetes Daniels, L.B. and Maisel, A.S., Cardiovascular biomarkers and sex: the case for women. Nat Rev Cardiol Jul 7. doi: /nrcardio [Epub ahead of print] Slide 64
65 Malmö Diet And Cancer Study pro-nt associated with cardiovascular mortality and CVD in females Slide 65
66 Malmö Diet And Cancer Study pro-nt predicts risk of inc. diabetes 1484 men and 2220 women 142 (68 men and 74 women) events event rate of 30.2 per person-years pro-nt only significant for women (P=.003) but not in men (P=.10) Relatively high pro-nt predicts risk of incident diabetes in women subjects with prevalent diabetes at baseline were excluded adjusted for age, sex, use of antihypertensive medication, systolic, blood pressure, BMI, waist circumference, prevalent cardiovascular disease, current smoking, and fasting concentrations of glucose, highdensity lipoprotein cholesterol (HDLC), LDL-C, triglycerides, and insulin (diabetes risk factors) Melander O et al., JAMA Oct 10;308(14): Slide 66
67 Breast Cancer Slide 67
68 OR Malmö Prevention Project confirms Proneurotensin is an independent predictor for incident breast cancer Relatively high pro-nt predicts risk of incident breast cancer 10 p for trend < Q1 Q2 Q3 Q4 pro-nt In MPP adjusted for age, antihypertensive medication, HRT, systolic blood pressure, BMI, current smoking, prevalent diabetes mellitus and cardiovascular disease and fasting concentrations of HDL-C, LDL-C MDC: Melander O et al., JAMA Oct 10;308(14): MPP: Melander O et al, 2014, Cancer Epidemiol Biomarkers Prev; 23(8); Slide 68
69 pro-nt [pmol/l] Influencing pro-nt levels by diet 350 For all with baseline pro-nt >200 pmol/l Subjects with baseline pro-nt above 200 pmol/l were on a lowfat diet for 8 weeks 300 P value < pro-nt was measured again after 8 weeks mean value of % change per subject: 25.2% (332 subjects) Upon a low-fat diet pro-nt decreased significantly Low-fat diet: A pro-nt-modulating intervention to decrease risk? 0 baseline 8 weeks low-fat diet Rudovich N.N., Pfeiffer A.F.H., unpublished Slide 69
70 The Promise of Personalized Medicine Genomic Profile Biomarker Profile Imaging Integrated Data Insight into Pathophysiology Clinical Data Individual Risk Assessment Predict response to a therapy Morrow DA ESC 2007; Adapted from West et al. Genome Research 2006; 16:
Biomarkers in the Age of Sacubitril/Valsa rten: Has the PARADIGM Changed
Biomarkers in the Age of Sacubitril/Valsa rten: Has the PARADIGM Changed Alan S. Maisel MD FACC Professor of Medicine, University of California, San Diego, Director, CCU and Heart Failure Program San Diego
More informationST2 in Heart Failure. ST2 as a Cardiovascular Biomarker. Competitive Model of ST2/IL-33 Signaling. ST2 and IL-33: Cardioprotective
ST2 as a Cardiovascular Biomarker Lori B. Daniels, MD, MAS, FACC Professor of Medicine Director, Coronary Care Unit University of California, San Diego ST2 and IL-33: Cardioprotective ST2: member of the
More information2017 ACC/AHA/HFSA HF guidelines. Advances in the Use of Biomarkers in Heart Failure Patients. Outline
Advances in the Use of Biomarkers in Heart Failure Patients Lori B. Daniels, MD, MAS, FACC, FAHA Professor of Medicine Director, Cardiovascular Intensive Care Unit Sulpizio Cardiovascular Center UC San
More informationUpdate on Biomarkers in Heart Failure. Professor T A McDonagh, King s College Hospital. London
Update on Biomarkers in Heart Failure Professor T A McDonagh, King s College Hospital. London Known Knowns,,,, for Biomarkers in HF Natriuretic Peptides Troponins BNP... ANP/BNP/ in CHF First to be discovered
More informationBiomarkers Now and in the Future of Emergency Medicine- TIME TO USE sst2 Alan S. Maisel MD FACC Professor of Medicine, Emeritus University of
Biomarkers Now and in the Future of Emergency Medicine- TIME TO USE sst2 Alan S. Maisel MD FACC Professor of Medicine, Emeritus University of California, San Diego, Chest Pain, Shortness of breath: We
More informationRisk Stratification in Heart Failure: The Role of Emerging Biomarkers
Risk Stratification in Heart Failure: The Role of Emerging Biomarkers David G. Grenache, PhD Associate Professor of Pathology, University of Utah Medical Director, ARUP Laboratories Salt Lake City, UT
More informationΒΙΟΔΕΙΚΤΕΣ ΣΤΗΝ ΚΑΡΔΙΑΚΗ ΑΝΕΠΑΡΚΕΙΑ. ΔΗΜΗΤΡΙΟΣ ΤΟΥΣΟΥΛΗΣ Καθηγητής Καρδιολογίας
ΕΘΝΙΚΟ ΚΑΙ ΚΑΠΟΔΙΣΤΡΙΑΚΟ ΠΑΝΕΠΙΣΤΗΜΙΟ ΑΘΗΝΩΝ ΙΑΤΡΙΚΗ ΣΧΟΛΗ Ά ΚΑΡΔΙΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ Διευθυντής: Καθηγητής Δημήτριος Τούσουλης ΒΙΟΔΕΙΚΤΕΣ ΣΤΗΝ ΚΑΡΔΙΑΚΗ ΑΝΕΠΑΡΚΕΙΑ ΔΗΜΗΤΡΙΟΣ ΤΟΥΣΟΥΛΗΣ Καθηγητής Καρδιολογίας
More informationNatriuretic Peptides The Cardiologists View. Christopher defilippi, MD University of Maryland Baltimore, MD, USA
Natriuretic Peptides The Cardiologists View Christopher defilippi, MD University of Maryland Baltimore, MD, USA Disclosures Research support: Alere, BG Medicine, Critical Diagnostics, Roche Diagnostics,
More informationRuolo dei Marcatori Bioumorali nello scompenso cardiaco
Ruolo dei Marcatori Bioumorali nello scompenso cardiaco Head Emergency Medicine Sant Andrea Hospital Director Postgraduate School of Emergency Medicine Faculty od Medicine and Psycology Sapienza University
More informationΒιοδείκτες στην καρδιακή ανεπάρκεια διαγνωστικά και θεραπευτικά δεδομένα. Χριστίνα Χρυσοχόου Επιμ Α Α Παν. Καρδιολογικής Κλινικής, ΙΓΝΑ
Βιοδείκτες στην καρδιακή ανεπάρκεια διαγνωστικά και θεραπευτικά δεδομένα Χριστίνα Χρυσοχόου Επιμ Α Α Παν. Καρδιολογικής Κλινικής, ΙΓΝΑ Παθοφυσιολογία καρδιακής ανεπάρκειας Kaye and Krum Nature Reviews
More information6/29/2017. Role of Biomarkers in the Management of Heart Failure Patients. What s New in Biomarkers for HF Patients?
What s New in Biomarkers for HF Patients? Role of Biomarkers in the Management of Heart Failure Patients Lori B. Daniels, MD, MAS, FACC Professor of Medicine Director, Cardiovascular Intensive Care Unit
More informationHeart Failure Biomarkers: Advances in Diagnostics and Therapeutics
Heart Failure Biomarkers: Advances in Diagnostics and Therapeutics Michael Felker, MD, MHS, FACC, FAHA Associate Professor of Medicine Director, Heart Failure Section Disclosures Consulting and/or Grant
More informationΟξεία καρδιακή ανεπάρκεια: Ποιες παράμετροι συμβάλλουν στη διαστρωμάτωση κινδύνου των ασθενών;
Οξεία καρδιακή ανεπάρκεια: Ποιες παράμετροι συμβάλλουν στη διαστρωμάτωση κινδύνου των ασθενών; Γ. Φιλιππάτος, MD, FACC, FESC, FCCP Επ. Καθηγητής Καρδιολογίας Πανεπ. Αθηνών Clinical Outcomes in Patients
More informationRole of Biomarkers for the Prevention, Assessment, and Management of Heart Failure: A Scientific Statement From the American Heart Association
Role of Biomarkers for the Prevention, Assessment, and Management of Heart Failure: A Scientific Statement From the American Heart Association We combed through both guidelines and summarized 3 recommendations
More informationA Guide to Proper Utilization of Biomarkers
A Guide to Proper Utilization of Biomarkers DR. ABEER BAKHSH CONSULTANT CARDIOLOGIST, ADVANCE HEART FAILURE KING FAHD ARMED FORCES HOSPITAL JEDDAH, SAUDI ARABIA Objective: Mechanism of myocardial injury
More informationBiomarker-guided HF: What have we learned (so far)?
Biomarker-guided HF: What have we learned (so far)? James L. Januzzi, Jr, MD, FACC, FESC Associate Professor of Medicine Harvard Medical School Director, Cardiac ICU Massachusetts General Hospital DECLARATION
More informationΟΙ ΒΙΟΔΕΙΚΤΕΣ ΚΑΡΔΙΟΛΟΓΙΑ ΣΗΜΕΡΑ ΔΗΜΗΤΡΙΟΣ ΤΟΥΣΟΥΛΗΣ. Καθηγητής Καρδιολογίας
ΕΘΝΙΚΟ ΚΑΙ ΚΑΠΟΔΙΣΤΡΙΑΚΟ ΠΑΝΕΠΙΣΤΗΜΙΟ ΑΘΗΝΩΝ ΙΑΤΡΙΚΗ ΣΧΟΛΗ Ά ΚΑΡΔΙΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ Διευθυντής: Καθηγητής Δημήτριος ΤΟΥΣΟΥΛΗΣ ΟΙ ΒΙΟΔΕΙΚΤΕΣ ΣΤΗΝ ΚΑΡΔΙΟΛΟΓΙΑ ΣΗΜΕΡΑ ΔΗΜΗΤΡΙΟΣ ΤΟΥΣΟΥΛΗΣ Καθηγητής Καρδιολογίας
More informationFrom PARADIGM-HF to Clinical Practice. Waleed AlHabeeb, MD, MHA Associate Professor of Medicine President of the Saudi Heart Failure Group
From PARADIGM-HF to Clinical Practice Waleed AlHabeeb, MD, MHA Associate Professor of Medicine President of the Saudi Heart Failure Group PARADIGM-HF: Inclusion Criteria Chronic HF NYHA FC II IV with LVEF
More informationManagement of chronic heart failure: update J. Parissis Attikon University Hospital
Management of chronic heart failure: update 2015 J. Parissis Attikon University Hospital Disclosures: received honoraria for lectures from Servier, Pfizer, Novartis Discharges in Thousands Heart Failure
More informationHEART FAILURE PATIENT MANAGEMENT. To The Power of 2!
HEART FAILURE PATIENT MANAGEMENT To The Power of 2! Put The Power of 2 To Work For You! THE PRESAGE ST2 ASSAY is a simple blood test that aids physicians in risk assessment of heart failure patients. Elevated
More informationImproving Diagnostic, Prognostic & Therapeutic Biomarkers in Heart Disease. Professor Mark Richards Medicine, University of Otago, Christchurch
Improving Diagnostic, Prognostic & Therapeutic Biomarkers in Heart Disease Professor Mark Richards Medicine, University of Otago, Christchurch BNP / NT-ProBNP H 2 N 1 Pro-BNP Cardiomyocyte 76 77 108 COOH
More informationThe Approach to Patients with Heart Failure and Mid-Range (40-50%) Ejection Fraction (HFmrEF)
The Approach to Patients with Heart Failure and Mid-Range (40-50%) Ejection Fraction (HFmrEF) 22 nd Annual Heart Failure 2018 an Update on Therapy April 21, 2018 Los Angeles, CA Barry Greenberg, M.D. Distinguished
More informationTreating HF Patients with ARNI s Why, When and How?
Treating HF Patients with ARNI s Why, When and How? 19 th Annual San Diego Heart Failure Symposium for Primary Care Physicians January 11-12, 2019 La Jolla, CA Barry Greenberg M.D. Distinguished Professor
More informationUPDATES IN MANAGEMENT OF HF
UPDATES IN MANAGEMENT OF HF Jennifer R Brown MD, MS Heart Failure Specialist Medstar Cardiology Associates DC ACP Meeting Fall 2017 Disclosures: speaker bureau for novartis speaker bureau for actelion
More informationHeart Failure and Cardio-Renal Syndrome 1: Pathophysiology. Biomarkers of Renal Injury and Dysfunction
CRRT 2011 San Diego, CA 22-25 February 2011 Heart Failure and Cardio-Renal Syndrome 1: Pathophysiology Biomarkers of Renal Injury and Dysfunction Dinna Cruz, M.D., M.P.H. Department of Nephrology San Bortolo
More informationHeart Failure Guidelines For your Daily Practice
Heart Failure Guidelines For your Daily Practice Juan M. Aranda, Jr., MD, FACC, FHFSA Professor of Medicine Director of Heart Failure and Cardiac Transplantation University of Florida College of Medicine
More informationDoppler ultrasound, see Ultrasonography. Magnetic resonance imaging (MRI), kidney oxygenation assessment 75
Subject Index Acidemia, cardiorenal syndrome type 3 146 Acute Dialysis Quality Initiative (ADQI) acute kidney injury biomarkers, see Acute kidney injury; specific biomarkers cardiorenal syndrome, see specific
More informationTreating the patient with acute heart failure. What do we really know? Principles of acute heart failure treatment
ESC 2012 27Aug - 3Sep, 2012, Munich, Germany Treating the patient with acute heart failure. What do we really know? Principles of acute heart failure treatment Marco Metra, MD, FESC Cardiology University
More information10 years evaluation of soluble ST2 level and incidence of diastolic
10 years evaluation of soluble ST2 level and incidence of diastolic dysfunction in EGAT study population Wisuit Katekao, MD Prin Vathesatogkit, MD Oraporn See, MD Sukit Yamwong, MD Piyamitr Sritara, MD
More informationTroponin Assessment. Does it Carry Clinical Message? Stefan Blankenberg. University Heart Center Hamburg
Biomarkers for Optimal Management of Heart Failure Troponin Assessment Does it Carry Clinical Message? Stefan Blankenberg University Heart Center Hamburg Congress of the European Society of Cardiology
More informationMeasuring Natriuretic Peptides in Acute Coronary Syndromes
Measuring Natriuretic Peptides in Acute Coronary Syndromes Peter A. McCullough, MD, MPH, FACC, FACP, FAHA, FCCP Consultant Cardiologist Chief Academic and Scientific Officer St. John Providence Health
More informationThe Dyspneic Patient in the ED Which Biomarkers should we use and how THIS COULD BE YOUR MOTHER
The Dyspneic Patient in the ED Which Biomarkers should we use and how THIS COULD BE YOUR MOTHER Diagnostic Biomarkers BNP Mid-region proanp Procalcitonin NGAL BIVA Prognostic Biomarkers Troponin Adrenomedulin
More informationAcute heart failure syndromes: clinical challenges. Pathophysiology. ESC Congress August. Paris, France. Marco Metra
ESC Congress 2011 27-31 August. Paris, France. Acute heart failure syndromes: clinical challenges. Pathophysiology Marco Metra Cardiology, Dept. Of experimental and applied medicine. University of Brescia.
More informationBiomarkers in the Assessment of Congestive Heart Failure
Biomarkers in the Assessment of Congestive Heart Failure Mid-Regional pro-adrenomedullin (MR-proADM) vs BNP & NT-proBNP as Prognosticator in Heart Failure Patients: Results of the BACH Multinational Trial
More informationThe ACC Heart Failure Guidelines
The ACC Heart Failure Guidelines Fakhr Alayoubi, Msc,R Ph President of SCCP Cardiology Clinical Pharmacist Assistant Professor At King Saud University King Khalid University Hospital Riyadh-KSA 2017 ACC/AHA/HFSA
More informationPearls in Acute Heart Failure Management
Pearls in Acute Heart Failure Management Best Practices Juan M. Aranda Jr., M.D. Professor of Medicine Medical Director of Heart Failure/ Transplant Program University of Florida College of Medicine Disclosures:
More informationÄr dagens troponinmetoder tillräckligt känsliga?
Är dagens troponinmetoder tillräckligt känsliga? Per Venge, MD PhD Professor Department of Medical Sciences Uppsala University and Department of Clinical Chemistry and Pharmacology University Hospital
More informationHeart failure (HF) is a complex clinical syndrome that results in the. impairment of the heart s ability to fill or to pump out blood.
Introduction: Heart failure (HF) is a complex clinical syndrome that results in the impairment of the heart s ability to fill or to pump out blood. As of 2013, an estimated 5.8 million people in the United
More informationBiomarkers in Heart Disease. Felix J. Rogers, DO, FACOI April 29, 2018
Biomarkers in Heart Disease Felix J. Rogers, DO, FACOI April 29, 2018 Biomarkers NIH: A biomarker is a characteristic that is objectively measured and evaluated as an indicator of normal biological processes,
More informationKeynote Address II Managing Acute Heart Failure: What Can We Do to Improve Outcomes?
Keynote Address II Managing Acute Heart Failure: What Can We Do to Improve Outcomes? 24 th Annual San Diego Heart Failure Symposium June 1-2, 2018 La Jolla, CA Barry Greenberg, MD Distinguished Professor
More informationTROPONINS HAVE THEY CHANGED YOUR
TROPONINS HAVE THEY CHANGED YOUR PRACTICE THIS WEEK? Harvey White John Neutze Scholar Green Lane Cardiovascular Service and Cardiovascular Research Unit Auckland City Hospital, Auckland, New Zealand Disclosure
More informationCorrelation of novel cardiac marker
Correlation of novel cardiac marker and mortality in EGAT population. Soluble ST2 hscrp Poh Chanyavanich, MD SukitYamwong, MD Piyamitr Sritara, MD Ramathibodi hospital Background hscrp - the most widely
More informationUpdates in Congestive Heart Failure
Updates in Congestive Heart Failure GREGORY YOST, DO JOHNSTOWN CARDIOVASCULAR ASSOCIATES 1/28/2018 Disclosures Edwards speaker on Sapien3 valves (TAVR) Stages A-D and NYHA Classes I-IV Stage A: High risk
More informationBiomarkers I: Defining the value of measuring
Biomarkers I: Defining the value of measuring Alan S. Maisel MD FACC Professor of Medicine, University of California, San Diego, Director, CCU and Heart Failure Program San Diego VA Medical Center The
More informationNatriuretic Peptide Guided Therapy for Heart Failure
Natriuretic Peptide Guided Therapy for Heart Failure Michael Felker, MD, MHS Associate Professor of Medicine Director of Heart Failure Research Duke Clinical Research Institute Disclosures Research Grants
More information2017 Summer MAOFP Update
2017 Summer MAOFP Update. Cardiology Update 2017 Landmark Trials Change Practice Guidelines David J. Strobl, DO, FNLA Heart Failure: Epidemiology More than 4 million patients affected 400,000 new cases
More informationPathophysiology and Diagnosis of Heart Failure
Pathophysiology and Diagnosis of Heart Failure Francesco Paneni, MD, PhD, FESC Cardiology Unit Karolinska University Hospital Stockholm, Sweden Cardiology University Hospital Zurich Switzerland francesco.paneni@gmail.com
More informationWhat s new in the 2017 heart failure guidelines. Prof.Dr.Mehmet Birhan YILMAZ, FESC, FACC, FHFA
What s new in the 2017 heart failure guidelines Prof.Dr.Mehmet Birhan YILMAZ, FESC, FACC, FHFA Key points to remember 2017 guidelines recommend using natriuretic peptides as biomarkers to screen for heart
More informationBiomarkers and Arrhythmias/Devices Ulrika Birgersdotter-Green, M.D.
Biomarkers and Arrhythmias/Devices Ulrika Birgersdotter-Green, M.D. Professor of Medicine Division of Cardiology University of California, San Diego Disclosures Honoraria, Research Grants, Medtronic Honoraria,
More informationBiomarkers beyond BNP and Troponin
Biomarkers beyond BNP and Troponin Alan Maisel, MD Professor of Medicine, University of California, San Diego Director, Coronary Care Unit and Heart Failure Program San Diego Veterans Hospital Disclosures
More informationBiomarkers in Acute Cardiac Disease Samir Arnaout, M.D.FESC Associate Professor of Medicine Internal Medicine i & Cardiology American University of Beirut Time course of the appearance of various markers
More informationDiagnosis is it really Heart Failure?
ESC Congress Munich - 25-29 August 2012 Heart Failure with Preserved Ejection Fraction From Bench to Bedside Diagnosis is it really Heart Failure? Prof. Burkert Pieske Department of Cardiology Med.University
More informationTherapeutic Targets and Interventions
Therapeutic Targets and Interventions Ali Valika, MD, FACC Advanced Heart Failure and Pulmonary Hypertension Advocate Medical Group Midwest Heart Foundation Disclosures: 1. Novartis: Speaker Honorarium
More informationOverview & Update on the Utilization of the Natriuretic Peptides in Heart Failure
June 28, 2016 Overview & Update on the Utilization of the Natriuretic Peptides in Heart Failure Linda C. Rogers, PhD, DABCC, FACB. Agenda Overview of the Natriuretic Peptides and Efficacy studies Similarities
More informationObjectives. Systolic Heart Failure: Definitions. Heart Failure: Historical Perspective 2/7/2009
Objectives Diastolic Heart Failure and Indications for Echocardiography in the Asian Population Damon M. Kwan, MD UCSF Asian Heart & Vascular Symposium 02.07.09 Define diastolic heart failure and differentiate
More informationCongestive Heart Failure: Outpatient Management
The Chattanooga Heart Institute Cardiovascular Symposium Congestive Heart Failure: Outpatient Management E. Philip Lehman MD, MPP Disclosure No financial disclosures. Objectives Evidence-based therapy
More informationCorporate Medical Policy
Corporate Medical Policy ST2 Assay for Chronic Heart Failure File Name: Origination: Last CAP Review: Next CAP Review: Last Review: st_assay_for_chronic_heart_failure 2/2015 4/2018 4/2019 4/2018 Description
More informationThe clinical value of natriuretic peptide testing in heart failure
The clinical value of natriuretic peptide testing in heart failure James L. Januzzi, Jr, MD, FACC, FESC Associate Professor of Medicine Harvard Medical School Roman W. DeSanctis Endowed Clinical Scholar
More informationBeta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes
Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes Seung-Jae Joo and other KAMIR-NIH investigators Department of Cardiology, Jeju National
More informationHeart Failure Management. Waleed AlHabeeb, MD, MHA Assistant Professor of Medicine Consultant Heart Failure Cardiologist
Heart Failure Management Waleed AlHabeeb, MD, MHA Assistant Professor of Medicine Consultant Heart Failure Cardiologist Heart failure prevalence is expected to continue to increase¹ 21 MILLION ADULTS WORLDWIDE
More informationDrugs acting on the reninangiotensin-aldosterone
Drugs acting on the reninangiotensin-aldosterone system John McMurray Eugene Braunwald Scholar in Cardiovascular Diseases, Brigham and Women s Hospital, Boston & Visiting Professor, Harvard Medical School
More informationBiomarkers and Arrhythmias/Devices Ulrika Birgersdotter-Green, MD, FHRS
Biomarkers and Arrhythmias/Devices Ulrika Birgersdotter-Green, MD, FHRS Professor of Medicine Division of Cardiology University of California, San Diego Disclosures Honoraria, Research Grants, Medtronic
More informationSystolic and Diastolic Dysfunction: Four Upcoming Challenges
Systolic and Diastolic Dysfunction: Four Upcoming Challenges Promoting Early Detection HFrEF: Beyond Neprilysin/Enalapril HFmrEF: What Is It and How Does One Manage It? HFpEF: Etiopathogenetic Role and
More informationStopping the Revolving Door of ADHF
Stopping the Revolving Door of ADHF Ileana L. Piña, MD, MPH Professor of Medicine and Epidemiology/Population Health Associate Chief for Academic Affairs -- Cardiology Montefiore-Einstein Medical Center
More informationHeart Failure in Women: Dr Goh Ping Ping Cardiologist Asian Heart & Vascular Centre
Heart Failure in Women: More than EF? Dr Goh Ping Ping Cardiologist Asian Heart & Vascular Centre Overview Review pathophysiology as it relates to diagnosis and management Rational approach to workup:
More informationOutline. Classification by LVEF Conventional Therapy New Therapies. Ivabradine Sacubitril/valsartan
New Pharmacological Therapies for Heart Failure Mark Drazner, MD, MSc Clinical Chief of Cardiology Medical Director, CHF/VAD/Transplant James M. Wooten Chair in Cardiology UT Southwestern Medical Center
More informationLCZ696 A First-in-Class Angiotensin Receptor Neprilysin Inhibitor
The Angiotensin Receptor Neprilysin Inhibitor LCZ696 in Heart Failure with Preserved Ejection Fraction The Prospective comparison of ARNI with ARB on Management Of heart failure with preserved ejection
More informationPitfalls in the use of biomarkers
Pitfalls in the use of biomarkers Alan Maisel MD Professor of Medicine, University of California, San Diego Director Coronary Care Unit And Heart Failure Program San Diego Veterans Hospital Disclosure
More informationACUTE HEART FAILURE. Julie Gorchynski MD, MSc, FACEP, FAAEM. Department of Emergency Medicine Emergency Residency Program UTHSC, San Antonio TCEP 2014
ACUTE HEART FAILURE Julie Gorchynski MD, MSc, FACEP, FAAEM Department of Emergency Medicine Emergency Residency Program UTHSC, San Antonio TCEP 2014 No disclosures Objectives Overview Cases Current Therapy
More informationEDUCATIONAL COMMENTARY CARDIAC FUNCTION: BIOCHEMICAL MARKERS UPDATE
EDUCATIONAL COMMENTARY CARDIAC FUNCTION: BIOCHEMICAL MARKERS UPDATE Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain FREE CME/CMLE
More informationPerformance and Quality Measures 1. NQF Measure Number. Coronary Artery Disease Measure Set
Unless indicated, the PINNACLE Registry measures are endorsed by the American College of Cardiology Foundation and the American Heart Association and may be used for purposes of health care insurance payer
More informationPravin Manga Division of Cardiology Department of Medicine University of Witwatersrand
Pravin Manga Division of Cardiology Department of Medicine University of Witwatersrand Overview Definition Epidemiology Biomarkers Treatment Clinical Heart Failure: Syndrome in which patients have typical
More informationHeart Failure Medical and Surgical Treatment
Heart Failure Medical and Surgical Treatment Daniel S. Yip, M.D. Medical Director, Heart Failure and Transplantation Mayo Clinic Second Annual Lakeland Regional Health Cardiovascular Symposium February
More informationHypertension, Remodelling and Novel Biomarkers in African Subjects
Hypertension, Remodelling and Novel Biomarkers in African Subjects Dike Ojji MBBS, PhD, FWACP, FACP, FESC Senior Lecturer, Department of Medicine, Faculty of Health Sciences, University of Abuja & Honorary
More informationAldosterone Antagonism in Heart Failure: Now for all Patients?
Aldosterone Antagonism in Heart Failure: Now for all Patients? Inder Anand, MD, FRCP, D Phil (Oxon.) Professor of Medicine, University of Minnesota, Director Heart Failure Program, VA Medical Center 111C
More informationHeart Failure. Cardiac Anatomy. Functions of the Heart. Cardiac Cycle/Hemodynamics. Determinants of Cardiac Output. Cardiac Output
Cardiac Anatomy Heart Failure Professor Qing ZHANG Department of Cardiology, West China Hospital www.blaufuss.org Cardiac Cycle/Hemodynamics Functions of the Heart Essential functions of the heart to cover
More informationHow might biomarkers and other strategies help establish adequacy of care?
How might biomarkers and other strategies help establish adequacy of care? James L. Januzzi, Jr, MD, FACC, FESC Hutter Family Professor of Medicine, Harvard Medical School Cardiology Division, Massachusetts
More informationHFpEF, Mito or Realidad?
HFpEF, Mito or Realidad? Ileana L. Piña, MD, MPH Professor of Medicine and Epidemiology/Population Health Associate Chief for Academic Affairs -- Cardiology Montefiore-Einstein Medical Center Bronx, NY
More informationPeri-operative Troponin Measurements - Pathophysiology and Prognosis
Peri-operative Troponin Measurements - Pathophysiology and Prognosis Allan S. Jaffe, MD.* Consultant - Cardiology & Laboratory Medicine Professor of Medicine Chair, CCLS Division, Department of Laboratory
More informationSatish K Surabhi, MD.FACC,FSCAI,RPVI Medical Director, Cardiac Cath Labs AnMed Health Heart & Vascular Care
Satish K Surabhi, MD.FACC,FSCAI,RPVI Medical Director, Cardiac Cath Labs AnMed Health Heart & Vascular Care None Fig. 1. Progression of Heart Failure.With each hospitalization for acute heart failure,
More informationHeFSSA Practitioners Program 2017 Theme The Patient Journey: Feel Good and Live Long. Case Study 2
HeFSSA Practitioners Program 2017 Theme The Patient Journey: Feel Good and Live Long Case Study 2 HEART FAILURE WITH MID-RANGE EJECTION FRACTION TREATMENT OPTIONS CLINICAL CASE MEDICAL HISTORY 59-year-old
More informationSleep Apnea and Heart Failure
Sleep Apnea and Heart Failure Micha T. Maeder, MD Cardiology Division Kantonsspital St. Gallen Switzerland micha.maeder@kssg.ch Sleep Disordered Breathing (SDB) in HFrEF 700 HFrEF patients (LVEF
More informationAkash Ghai MD, FACC February 27, No Disclosures
Akash Ghai MD, FACC February 27, 2015 No Disclosures Epidemiology Lifetime risk is > 20% for American s older than 40 years old. > 650,000 new cases diagnosed each year. Incidence increases with age: 2%
More informationFOCUS ON CARDIOVASCULAR DISEASE
The Consequences of Vitamin D Deficiency: FOCUS ON CARDIOVASCULAR DISEASE Vitamin D deficiency is a global health problem. With all the medical advances of the century, vitamin D deficiency is still epidemic.
More informationDiabetes and the Heart
Diabetes and the Heart Association of Specialty Professors April 4, 2013 Jorge Plutzky, MD Co-Director, Preventive Cardiology Director, The Lipid Clinic Cardiovascular Division Brigham and Women s Hospital
More informationThe Failing Heart in Primary Care
The Failing Heart in Primary Care Hamid Ikram How fares the Heart Failure Epidemic? 4357 patients, 57% women, mean age 74 years HFSA 2010 Practice Guideline (3.1) Heart Failure Prevention A careful and
More informationRevascularization in Severe LV Dysfunction: The Role of Inducible Ischemia and Viability Testing
Revascularization in Severe LV Dysfunction: The Role of Inducible Ischemia and Viability Testing Evidence and Uncertainties Robert O. Bonow, MD, MS, MACC Northwestern University Feinberg School of Medicine
More informationHEART FAILURE IN WOMEN. Marian Limacher, MD Division of Cardiovascular Medicine University of Florida
HEART FAILURE IN WOMEN Marian Limacher, MD Division of Cardiovascular Medicine University of Florida Outline Epidemiology Clinical Overview Why HF is such a challenge State of the Field Heart Failure Adjudication
More informationDiabetes and Heart Failure
Diabetes and Heart Failure A common and fatal combination A Aspects on epidemiology, prognosis diagnosis and therapy Lars Rydén Department of Medicine Karolinska Institutet Stockholm, Sweden Diabetes and
More informationLearning Objectives. Predicting and Preventing Cardiovascular Disease. ACC/AHA Cholesterol Guidelines Key differences vs ATP III
Presenter Disclosure Information 10:30 11:15am Predicting and Preventing Cardiovascular Disease: Can we put the Cardiologist out of business? The following relationships exist related to this presentation:
More informationIn Vivo Animal Models of Heart Disease. Why Animal Models of Disease? Timothy A Hacker, PhD Department of Medicine University of Wisconsin-Madison
In Vivo Animal Models of Heart Disease Timothy A Hacker, PhD Department of Medicine University of Wisconsin-Madison Why Animal Models of Disease? Heart Failure (HF) Leading cause of morbidity and mortality
More informationHeart Failure 101 The Basic Principles of Diagnosis & Management
Heart Failure 101 The Basic Principles of Diagnosis & Management Bill Tran, MD Non Invasive Cardiologist February 24, 2018 What the eye does not see and the mind does not know, does not exist. DH Lawrence
More informationHeart Failure: Combination Treatment Strategies
Heart Failure: Combination Treatment Strategies M. McDonald MD, FRCP State of the Heart Symposium May 28, 2011 None Disclosures Case 69 F, prior MIs (LV ejection fraction 25%), HTN No demonstrable ischemia
More informationCurrent Utilities of Cardiac Biomarker Testing at POC. June 24, 2010 Joe Pezzuto, MT (ASCP) Carolyn Kite, RN
Current Utilities of Cardiac Biomarker Testing at POC June 24, 2010 Joe Pezzuto, MT (ASCP) Carolyn Kite, RN 1. Discuss challenges associated with diagnosing Acute Coronary Syndromes (ACS) and Heart Failure
More informationClinical Phenotypes and In-hospital Management and Prognosis in Diabetic versus Non-diabetic Patients with Acute Heart Failure in ALARM-HF Registry
Clinical Phenotypes and In-hospital Management and Prognosis in Diabetic versus Non-diabetic Patients with Acute Heart Failure in ALARM-HF Registry J T. Parissis, A. Mebazaa, V. Bistola, I. Ikonomidis,
More informationOxford Medicine Online
Oxford Medicine Online The ESC Textbook of Intensive and Acute Cardiovascular Care (2 ed.) Edited by Marco Tubaro, Pascal Vranckx, Susanna Price, and Christiaan Vrints Latest update This online textbook
More informationThe role of remote monitoring in preventing readmissions after acute heart failure
The role of remote monitoring in preventing readmissions after acute heart failure October 20, 2017 Randall C Starling MD MPH FACC FAHA FESA FHFSA Professor of Medicine Kaufman Center for Heart Failure
More informationHeart Failure. A Marvellous Story with More to Come. Prof Ken McDonald National Clinical Lead for Heart Failure
Heart Failure A Marvellous Story with More to Come Prof Ken McDonald National Clinical Lead for Heart Failure Advances in Heart Failure over Last 20 years Pharmacotherapy in HF-REF ADHF 50-15% Community
More informationMedical management of LV aneurysm and subsequent cardiac remodeling: is it enough? J. Parissis Attikon University Hospital Athens, Greece
Medical management of LV aneurysm and subsequent cardiac remodeling: is it enough? J. Parissis Attikon University Hospital Athens, Greece Disclosures Grants: ALARM investigator received research grants
More information2/11/2017. Weighing the Heavy Cardiovascular Burden of Obesity and the Obesity Paradox. Disclosures. Carl J. Lavie, MD, FACC, FACP, FCCP
Weighing the Heavy Cardiovascular Burden of Obesity and the Obesity Paradox Carl J. Lavie, MD, FACC, FACP, FCCP Professor of Medicine Medical Director, Cardiac Rehabilitation and Preventive Cardiology
More information